NICE has published its final guidance recommending tenecteplase (also called Metalyse and made by Boehringer Ingelheim) as an option for treating acute ischaemic stroke in adults.

Up to 2.1 million people with cardiovascular disease (CVD) could benefit from a new cholesterol target outlined in NICE guidance for the first time.

An independent NICE committee has recommended people whose diabetes is not controlled with their current device despite best possible management with an insulin pump, or real-time or intermittently scanned continuous glucose monitoring, are offered a hybrid closed loop system.

Around 180,000 people with difficult to manage type 2 diabetes could benefit from a new treatment option.